Literature DB >> 36003714

Commentary: What do we still have to learn from surgery?

Igor Belluschi1, Mattia Glauber2, Antonio Miceli2.   

Abstract

Entities:  

Year:  2021        PMID: 36003714      PMCID: PMC9390765          DOI: 10.1016/j.xjon.2021.06.014

Source DB:  PubMed          Journal:  JTCVS Open        ISSN: 2666-2736


× No keyword cloud information.
Igor Belluschi, MD, Mattia Glauber, MD, and Antonio Miceli, MD Biomechanical analysis explains the dynamics beyond papillary muscle approximation as an emerging treatment for functional mitral regurgitation. See Article page 91. The mitral valve apparatus represents an example of how nature designs a perfect, harmonic, and functional body structure, like a fascinating and solid renaissance cathedral. However, this beautiful architecture can be damaged by external events, such as atmospheric agents and earthquakes, requiring conservative restoration whenever possible. Similarly, the effect of different diseases, such as myocardial infarction, myocarditis, or eccentric hypertrophy, may damage the whole mitral valve architecture, requiring interventions. Functional mitral regurgitation (FMR) is the result of the posterior and lateral dislocation of papillary muscles, which leads to apical leaflet tethering and lack of coaptation. When the geometry is fully distorted, repair strategies cannot guarantee optimal and durable results, and valve replacement may remain the only available solution. On the contrary, an undersized annuloplasty can force coaptation and decreases regurgitant jet in less-challenging anatomies. The advantage of valve repair over replacement in the context of ischemic mitral regurgitation has been long debated, but previous series showed that repair is associated with lower perioperative mortality, despite an increased risk of mitral regurgitation recurrence. The high rate of repair failure could be related to the subvalvular mitral dysfunction, which is not often addressed, leaving tension on the leaflet because of left ventricular enlargement. Furthermore, undersized annuloplasty also could result in increased transvalvular gradient, due to extreme tethering, which paradoxically limit leaflet excursion. In this setting, several surgical techniques have been proposed: chordal transection, anterior leaflet augmentation, relocation, and approximation of the papillary muscles. The latter, which consists in approximating the tips of 2 papillary muscles with pledget sutures, has shown promising mid-term results, especially when compared with annuloplasty alone., Its aim is to relief the tethering forces on the leaflets and restores coaptation geometry. However, no data on the mechanics of such treated valve have yet been reported. So, what are we missing to improve FMR repairability? In this issue of the Journal, Zhan-Moodie and colleagues provided an ex vivo model of FMR, combining papillary muscle approximation and 2 complete annuloplasty rings (true dimension 30 mm vs undersized 26 mm). The most significant results were obtained when papillary muscle approximation was associated to the undersized ring, showing lower regurgitant fraction (from a mean of 16% to 4%), lower tenting area (83-22 mm2), lower height (11-4 mm), and augmented coaptation length. Leaflet mobility was restored as well, due to an increased leaflet excursion angles and a reduction of chordal forces. Furthermore, this simple procedure on the papillary muscles also could allow leaflet mobilization also associated with larger annular rings. As a result, authors suggest that rings of larger sizes may be used if combined to muscle approximation, thus avoiding the risk of stenosis linked to undersizing. However, major drawbacks of this model are the choice of isolated swine healthy mitral valves and the lack of either concomitant ventricle dynamics and pathologic fibrotic tissue. For the first time, this study provides biomechanical data on papillary muscle approximation in association with annuloplasty, showing relief of tethering forces on leaflet during systole and better coaptation. Whilst surgeons are still debating about the treatment of choice, the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial has easily demonstrated that percutaneous repair can treat FMR. Nevertheless, the translational analysis by Zhan-Moodie and colleagues is evidence that we have still something to learn from surgery. However, not all questions have been answered yet: will there be a role for a percutaneous papillary muscle approximation?
  9 in total

Review 1.  Meta-analysis of results of subvalvular repair for severe ischemic mitral regurgitation.

Authors:  Massimo Meco; Antonio Lio; Andrea Montisci; Paolo Panisi; Matteo Ferrarini; Antonio Miceli; Mattia Glauber
Journal:  J Card Surg       Date:  2020-03-11       Impact factor: 1.620

2.  Commentary: A device for the whole mitral valve apparatus.

Authors:  Antonio Miceli
Journal:  J Thorac Cardiovasc Surg       Date:  2020-12-13       Impact factor: 5.209

3.  Ischaemic mitral regurgitation: pathophysiology, outcomes and the conundrum of treatment.

Authors:  Luc A Piérard; Blase A Carabello
Journal:  Eur Heart J       Date:  2010-12-01       Impact factor: 29.983

4.  Is repair preferable to replacement for ischemic mitral regurgitation?

Authors:  A M Gillinov; P N Wierup; E H Blackstone; E S Bishay; D M Cosgrove; J White; B W Lytle; P M McCarthy
Journal:  J Thorac Cardiovasc Surg       Date:  2001-12       Impact factor: 5.209

5.  Functional mitral stenosis after mitral valve repair for Type II dysfunction: determinants and impacts on long-term outcome.

Authors:  Naonori Kawamoto; Tomoyuki Fujita; Satsuki Fukushima; Yusuke Shimahara; Yuta Kume; Yorihiko Matsumoto; Kizuku Yamashita; Koko Asakura; Junjiro Kobayashi
Journal:  Eur J Cardiothorac Surg       Date:  2018-09-01       Impact factor: 4.191

6.  Predicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitation.

Authors:  Irving L Kron; Judy Hung; Jessica R Overbey; Denis Bouchard; Annetine C Gelijns; Alan J Moskowitz; Pierre Voisine; Patrick T O'Gara; Michael Argenziano; Robert E Michler; Marc Gillinov; John D Puskas; James S Gammie; Michael J Mack; Peter K Smith; Chittoor Sai-Sudhakar; Timothy J Gardner; Gorav Ailawadi; Xin Zeng; Karen O'Sullivan; Michael K Parides; Roger Swayze; Vinod Thourani; Eric A Rose; Louis P Perrault; Michael A Acker
Journal:  J Thorac Cardiovasc Surg       Date:  2014-11-06       Impact factor: 5.209

7.  Transcatheter Mitral-Valve Repair in Patients with Heart Failure.

Authors:  Gregg W Stone; JoAnn Lindenfeld; William T Abraham; Saibal Kar; D Scott Lim; Jacob M Mishell; Brian Whisenant; Paul A Grayburn; Michael Rinaldi; Samir R Kapadia; Vivek Rajagopal; Ian J Sarembock; Andreas Brieke; Steven O Marx; David J Cohen; Neil J Weissman; Michael J Mack
Journal:  N Engl J Med       Date:  2018-09-23       Impact factor: 91.245

8.  Papillary Muscle Approximation Reduces Systolic Tethering Forces and Improves Mitral Valve Closure in the Repair of Functional Mitral Regurgitation.

Authors:  Samantha Zhan-Moodie; Dongyang Xu; Kirthana Sreerangathama Suresh; Qi He; Daisuke Onohara; Kanika Kalra; Robert A Guyton; Eric L Sarin; Muralidhar Padala
Journal:  JTCVS Open       Date:  2021-04-28

9.  The extent of papillary muscle approximation affects mortality and durability of mitral valve repair for ischemic mitral regurgitation.

Authors:  Satoru Wakasa; Suguru Kubota; Yasushige Shingu; Tomonori Ooka; Tsuyoshi Tachibana; Yoshiro Matsui
Journal:  J Cardiothorac Surg       Date:  2014-06-03       Impact factor: 1.637

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.